News GSK gets June 2023 FDA decision date for momelotinib The clock is now ticking on the FDA's review of GSK's momelotinib for myelofibrosis patients with anaemia – the centrepiece of its $1.9 billion
News GSK bolsters cancer pipeline with $1.9bn Sierra Oncology buy GlaxoSmithKline has agreed a deal to buy Sierra Oncology and its lead drug momelotinib for anaemia associated with the blood cancer myelofibrosis, sending the US biotech's shares skywards.<
News Amid sector disruption, biotech must focus on 'fundamentals'... The biotech industry in the US is facing a period of deep uncertainty under the Trump administration, but can ride out the storm, says EY.
Market Access The value of a partner, globally and locally A new podcast looks at recent trends related to drug approvals, as well as challenges and opportunities both small and large pharma companies face